SEC Form 4 · accession 0001179110-16-021475
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Avery W Catlin
Officer — Sr. VP & CFO
Period of report
Mar 9, 2016
Accepted (ET)
Mar 10, 2016 · 7:59 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1 | Mar 9, 2016 | M | 15,000 | $2.80 | A | 50,739 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF2 | $2.80 | Mar 9, 2016 | M | 15,000 | D | Aug 5, 2012 | Aug 5, 2021 | Common Stock | 15,000 | 20,000 | D |
Explanation of responses
- F1Includes 630 shares of common stock acquired under the Company's 2004 Employee Stock Purchase Plan on December 31, 2015.
- F2As of August 5,2015, the option is fully vested.